Published
{
"ticker": "DHR",
"cik": "0000313616",
"company": "Danaher Corporation",
"business_type": "industrial",
"schema_template": "standard industrial (life sciences and diagnostics): sales, cost of sales, gross profit, SG&A, R&D, operating profit, non-operating items, income taxes, earnings from continuing and discontinued operations, net earnings, basic and diluted EPS and weighted shares; the full balance sheet with total debt; operating, investing and financing cash flow from continuing operations with capital expenditures and free cash flow; dividends and buybacks; sales and operating profit for the Biotechnology, Life Sciences and Diagnostics segments; and Danaher's own non-GAAP adjusted EPS, free cash flow and core sales growth from its earnings release",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual US dollars (not millions); per-share amounts in dollars; share counts in actual shares; growth rates in percent",
"units_notes_seen": {
"FY2025 10-K consolidated statements of earnings": "($ and shares in millions, except per share amounts)",
"FY2025 10-K consolidated balance sheets": "($ in millions, except per share amount)",
"FY2025 10-K consolidated statements of stockholders' equity": "($ in millions)",
"FY2025 10-K consolidated statements of cash flows": "($ in millions)",
"FY2025 10-K segment information (Note 6)": "Detailed segment data is as follows ($ in millions)",
"Q3 2026 10-Q consolidated condensed statements of earnings": "($ and shares in millions, except per share amounts)",
"Q3 2026 10-Q consolidated condensed balance sheets": "($ in millions, except per share amount)",
"Q3 2026 10-Q consolidated condensed statements of stockholders' equity": "($ in millions)",
"Q3 2026 10-Q consolidated condensed statements of cash flows (nine months only)": "($ in millions)",
"Q3 2026 10-Q segment information (Note 6)": "Detailed segment data for the three and nine-month periods ended September 25, 2026 and September 26, 2025 is as follows ($ in millions)",
"Q3 2026 earnings release statements of earnings": "($ and shares in millions, except per share amounts)",
"Q3 2026 earnings release cash flow and free cash flow reconciliation": "($ in millions)",
"Q3 2026 earnings release adjusted diluted EPS reconciliation": "per-share amounts in dollars; growth table in percent"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none; Danaher reports in US dollars",
"split_note": "No stock split affects these periods. The September 30, 2023 distribution of Veralto Corporation shares (one Veralto share for every three Danaher shares) was a spin-off, not a split; the filings do not restate per-share figures for it and none have been adjusted here."
},
"definitions": {
"revenue": "the line the statements caption 'Sales'",
"cost_of_sales, selling_general_and_administrative_expenses, research_and_development_expenses, interest_expense": "stated as positive amounts (the statements print them in parentheses as deductions)",
"income_tax_expense": "positive = tax expense, negative = tax benefit; Q3 FY2026 is a net benefit of $75 million",
"other_income_expense_net": "as printed: negative = net expense",
"operating_cash_flow": "net cash provided by operating activities from continuing operations; the annual periods also carry the total including discontinued operations",
"capital_expenditures": "payments for additions to property, plant and equipment, stated as a positive amount",
"free_cash_flow": "operating cash flow from continuing operations less capital expenditures. Danaher's own non-GAAP free cash flow also adds back proceeds from sales of property, plant and equipment; that figure is shown separately as non_gaap.free_cash_flow_company_definition",
"net_cash_from_investing_activities_continuing_operations, net_cash_from_financing_activities_continuing_operations": "signed as printed: negative = cash used",
"total_liabilities": "derived: total current liabilities + other long-term liabilities + long-term debt (the balance sheet prints no total-liabilities line); equals total assets less total stockholders' equity",
"total_debt": "notes payable and current portion of long-term debt + long-term debt",
"shares_outstanding": "common shares outstanding at period end, from the balance sheet caption",
"treasury_stock, accumulated_other_comprehensive_income_loss": "signed as printed: negative = reduction of equity"
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0000313616-26-000062",
"income_statement": {
"revenue": 24568000000,
"cost_of_sales": 10045000000,
"gross_profit": 14523000000,
"selling_general_and_administrative_expenses": 8235000000,
"research_and_development_expenses": 1598000000,
"operating_profit": 4690000000,
"other_income_expense_net": -222000000,
"interest_expense": 265000000,
"interest_income": 30000000,
"earnings_from_continuing_operations_before_income_taxes": 4233000000,
"income_tax_expense": 633000000,
"net_earnings_from_continuing_operations": 3600000000,
"earnings_from_discontinued_operations_net_of_tax": 14000000,
"net_earnings": 3614000000,
"basic_eps_continuing_operations": 5.05,
"diluted_eps_continuing_operations": 5.03,
"basic_eps_discontinued_operations": 0.02,
"diluted_eps_discontinued_operations": 0.02,
"basic_eps": 5.07,
"diluted_eps": 5.05,
"basic_shares": 712700000,
"diluted_shares": 716100000,
"preferred_stock_dividends": 0,
"net_earnings_attributable_to_common_stockholders": 3614000000
},
"balance_sheet": {
"cash_and_equivalents": 4615000000,
"trade_accounts_receivable_net": 3913000000,
"inventories": 2489000000,
"prepaid_expenses_and_other_current_assets": 1739000000,
"total_current_assets": 12756000000,
"property_plant_and_equipment_net": 5531000000,
"other_long_term_assets": 4209000000,
"goodwill": 43151000000,
"other_intangible_assets_net": 17817000000,
"total_assets": 83464000000,
"notes_payable_and_current_portion_of_long_term_debt": 2000000,
"trade_accounts_payable": 1844000000,
"accrued_expenses_and_other_liabilities": 4961000000,
"total_current_liabilities": 6807000000,
"other_long_term_liabilities": 5700000000,
"long_term_debt": 18416000000,
"common_stock": 9000000,
"additional_paid_in_capital": 17194000000,
"treasury_stock": -11353000000,
"retained_earnings": 46891000000,
"accumulated_other_comprehensive_income_loss": -207000000,
"total_danaher_stockholders_equity": 52534000000,
"noncontrolling_interests": 7000000,
"total_equity": 52541000000,
"total_liabilities": 30923000000,
"total_debt": 18418000000,
"shares_outstanding": 706900000
},
"cash_flow": {
"depreciation": 750000000,
"amortization_of_intangible_assets": 1697000000,
"stock_based_compensation": 298000000,
"impairment_charges": 562000000,
"operating_cash_flow": 6416000000,
"operating_cash_flow_including_discontinued_operations": 6416000000,
"cash_paid_for_acquisitions": 0,
"capital_expenditures": 1156000000,
"proceeds_from_sales_of_property_plant_and_equipment": 33000000,
"net_cash_from_investing_activities_continuing_operations": -1196000000,
"dividends_paid": 878000000,
"borrowings_maturities_longer_than_90_days": 1556000000,
"repayments_of_borrowings_maturities_longer_than_90_days": 500000000,
"payments_for_repurchase_of_common_stock": 3088000000,
"net_cash_from_financing_activities_continuing_operations": -2961000000,
"free_cash_flow": 5260000000
},
"shareholder_returns": {
"common_stock_dividends_declared": 911000000,
"repurchase_of_common_stock_including_excise_tax": 3112000000,
"dividends_paid": 878000000,
"payments_for_repurchase_of_common_stock": 3088000000
},
"segments": {
"biotechnology": {
"sales": 7293000000,
"operating_profit": 1864000000
},
"life_sciences": {
"sales": 7334000000,
"operating_profit": 520000000
},
"diagnostics": {
"sales": 9941000000,
"operating_profit": 2650000000
},
"total_reportable_segments": {
"sales": 24568000000,
"operating_profit": 5034000000
},
"other_unallocated_corporate": {
"operating_profit": -344000000
}
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0000313616-26-000062",
"income_statement": {
"revenue": 23875000000,
"cost_of_sales": 9669000000,
"gross_profit": 14206000000,
"selling_general_and_administrative_expenses": 7759000000,
"research_and_development_expenses": 1584000000,
"operating_profit": 4863000000,
"other_income_expense_net": -56000000,
"interest_expense": 278000000,
"interest_income": 117000000,
"earnings_from_continuing_operations_before_income_taxes": 4646000000,
"income_tax_expense": 747000000,
"net_earnings_from_continuing_operations": 3899000000,
"earnings_from_discontinued_operations_net_of_tax": 0,
"net_earnings": 3899000000,
"basic_eps_continuing_operations": 5.33,
"diluted_eps_continuing_operations": 5.29,
"basic_eps_discontinued_operations": 0,
"diluted_eps_discontinued_operations": 0,
"basic_eps": 5.33,
"diluted_eps": 5.29,
"basic_shares": 731000000,
"diluted_shares": 737200000,
"preferred_stock_dividends": 0,
"net_earnings_attributable_to_common_stockholders": 3899000000
},
"balance_sheet": {
"cash_and_equivalents": 2078000000,
"trade_accounts_receivable_net": 3537000000,
"inventories": 2330000000,
"prepaid_expenses_and_other_current_assets": 1552000000,
"total_current_assets": 9497000000,
"property_plant_and_equipment_net": 4990000000,
"other_long_term_assets": 3990000000,
"goodwill": 40497000000,
"other_intangible_assets_net": 18568000000,
"total_assets": 77542000000,
"notes_payable_and_current_portion_of_long_term_debt": 505000000,
"trade_accounts_payable": 1753000000,
"accrued_expenses_and_other_liabilities": 4540000000,
"total_current_liabilities": 6798000000,
"other_long_term_liabilities": 5694000000,
"long_term_debt": 15500000000,
"common_stock": 9000000,
"additional_paid_in_capital": 16727000000,
"treasury_stock": -8163000000,
"retained_earnings": 44188000000,
"accumulated_other_comprehensive_income_loss": -3218000000,
"total_danaher_stockholders_equity": 49543000000,
"noncontrolling_interests": 7000000,
"total_equity": 49550000000,
"total_liabilities": 27992000000,
"total_debt": 16005000000,
"shares_outstanding": 719100000
},
"cash_flow": {
"depreciation": 721000000,
"amortization_of_intangible_assets": 1631000000,
"stock_based_compensation": 288000000,
"impairment_charges": 265000000,
"operating_cash_flow": 6688000000,
"operating_cash_flow_including_discontinued_operations": 6688000000,
"cash_paid_for_acquisitions": 558000000,
"capital_expenditures": 1392000000,
"proceeds_from_sales_of_property_plant_and_equipment": 13000000,
"net_cash_from_investing_activities_continuing_operations": -1981000000,
"dividends_paid": 768000000,
"borrowings_maturities_longer_than_90_days": 0,
"repayments_of_borrowings_maturities_longer_than_90_days": 1674000000,
"payments_for_repurchase_of_common_stock": 5979000000,
"net_cash_from_financing_activities_continuing_operations": -8385000000,
"free_cash_flow": 5296000000
},
"shareholder_returns": {
"common_stock_dividends_declared": 785000000,
"repurchase_of_common_stock_including_excise_tax": 6039000000,
"dividends_paid": 768000000,
"payments_for_repurchase_of_common_stock": 5979000000
},
"segments": {
"biotechnology": {
"sales": 6759000000,
"operating_profit": 1685000000
},
"life_sciences": {
"sales": 7329000000,
"operating_profit": 879000000
},
"diagnostics": {
"sales": 9787000000,
"operating_profit": 2625000000
},
"total_reportable_segments": {
"sales": 23875000000,
"operating_profit": 5189000000
},
"other_unallocated_corporate": {
"operating_profit": -326000000
}
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0000313616-26-000062",
"income_statement": {
"revenue": 23890000000,
"cost_of_sales": 9856000000,
"gross_profit": 14034000000,
"selling_general_and_administrative_expenses": 7329000000,
"research_and_development_expenses": 1503000000,
"operating_profit": 5202000000,
"other_income_expense_net": -175000000,
"interest_expense": 286000000,
"interest_income": 303000000,
"earnings_from_continuing_operations_before_income_taxes": 5044000000,
"income_tax_expense": 823000000,
"net_earnings_from_continuing_operations": 4221000000,
"earnings_from_discontinued_operations_net_of_tax": 543000000,
"net_earnings": 4764000000,
"basic_eps_continuing_operations": 5.7,
"diluted_eps_continuing_operations": 5.65,
"basic_eps_discontinued_operations": 0.74,
"diluted_eps_discontinued_operations": 0.73,
"basic_eps": 6.44,
"diluted_eps": 6.38,
"basic_shares": 736500000,
"diluted_shares": 743100000,
"preferred_stock_dividends": 21000000,
"net_earnings_attributable_to_common_stockholders": 4743000000
},
"cash_flow": {
"depreciation": 675000000,
"amortization_of_intangible_assets": 1491000000,
"stock_based_compensation": 306000000,
"impairment_charges": 77000000,
"operating_cash_flow": 6490000000,
"operating_cash_flow_including_discontinued_operations": 7164000000,
"cash_paid_for_acquisitions": 5610000000,
"capital_expenditures": 1383000000,
"proceeds_from_sales_of_property_plant_and_equipment": 12000000,
"net_cash_from_investing_activities_continuing_operations": -7048000000,
"dividends_paid": 821000000,
"borrowings_maturities_longer_than_90_days": 0,
"repayments_of_borrowings_maturities_longer_than_90_days": 620000000,
"payments_for_repurchase_of_common_stock": 0,
"net_cash_from_financing_activities_continuing_operations": 154000000,
"free_cash_flow": 5107000000
},
"shareholder_returns": {
"common_stock_dividends_declared": 773000000,
"repurchase_of_common_stock_including_excise_tax": 0,
"dividends_paid": 821000000,
"payments_for_repurchase_of_common_stock": 0
},
"segments": {
"biotechnology": {
"sales": 7172000000,
"operating_profit": 1909000000
},
"life_sciences": {
"sales": 7141000000,
"operating_profit": 1209000000
},
"diagnostics": {
"sales": 9577000000,
"operating_profit": 2406000000
},
"total_reportable_segments": {
"sales": 23890000000,
"operating_profit": 5524000000
},
"other_unallocated_corporate": {
"operating_profit": -322000000
}
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 3,
"label": "Q3 FY2026",
"period_start": "2026-06-27",
"period_end": "2026-09-25",
"period_type": "three months",
"source_accession": "0000313616-26-000199",
"income_statement": {
"revenue": 6554000000,
"cost_of_sales": 2717000000,
"gross_profit": 3837000000,
"selling_general_and_administrative_expenses": 2159000000,
"research_and_development_expenses": 433000000,
"operating_profit": 1245000000,
"other_income_expense_net": -9000000,
"interest_expense": 135000000,
"interest_income": 31000000,
"earnings_from_continuing_operations_before_income_taxes": 1132000000,
"income_tax_expense": -75000000,
"net_earnings_from_continuing_operations": 1207000000,
"earnings_from_discontinued_operations_net_of_tax": 28000000,
"net_earnings": 1235000000,
"basic_eps_continuing_operations": 1.71,
"diluted_eps_continuing_operations": 1.71,
"basic_eps_discontinued_operations": 0.04,
"diluted_eps_discontinued_operations": 0.04,
"basic_eps": 1.75,
"diluted_eps": 1.75,
"basic_shares": 703800000,
"diluted_shares": 706800000
},
"balance_sheet": {
"cash_and_equivalents": 5682000000,
"trade_accounts_receivable_net": 4126000000,
"inventories": 3134000000,
"prepaid_expenses_and_other_current_assets": 1845000000,
"total_current_assets": 14787000000,
"property_plant_and_equipment_net": 5773000000,
"other_long_term_assets": 4354000000,
"goodwill": 47315000000,
"other_intangible_assets_net": 21052000000,
"total_assets": 93281000000,
"notes_payable_and_current_portion_of_long_term_debt": 2094000000,
"trade_accounts_payable": 1742000000,
"accrued_expenses_and_other_liabilities": 5214000000,
"total_current_liabilities": 9050000000,
"other_long_term_liabilities": 6210000000,
"long_term_debt": 24388000000,
"common_stock": 9000000,
"additional_paid_in_capital": 17628000000,
"treasury_stock": -12330000000,
"retained_earnings": 49179000000,
"accumulated_other_comprehensive_income_loss": -865000000,
"total_danaher_stockholders_equity": 53621000000,
"noncontrolling_interests": 12000000,
"total_equity": 53633000000,
"total_liabilities": 39648000000,
"total_debt": 26482000000,
"shares_outstanding": 703400000
},
"cash_flow": {
"operating_cash_flow": 1886000000,
"capital_expenditures": 255000000,
"proceeds_from_sales_of_property_plant_and_equipment": 1000000,
"net_cash_from_investing_activities_continuing_operations": -300000000,
"net_cash_from_financing_activities_continuing_operations": -262000000,
"free_cash_flow": 1631000000
},
"cash_flow_source_accession": "0000313616-26-000201",
"shareholder_returns": {
"common_stock_dividends_declared": 282000000,
"repurchase_of_common_stock_including_excise_tax": 0
},
"segments": {
"biotechnology": {
"sales": 1807000000,
"operating_profit": 477000000
},
"life_sciences": {
"sales": 1865000000,
"operating_profit": 259000000
},
"diagnostics": {
"sales": 2882000000,
"operating_profit": 614000000
},
"total_reportable_segments": {
"sales": 6554000000,
"operating_profit": 1350000000
},
"other_unallocated_corporate": {
"operating_profit": -105000000
}
},
"non_gaap": {
"adjusted_diluted_eps_continuing_operations": 2.11,
"free_cash_flow_company_definition": 1632000000,
"core_sales_growth_pct": 3.0,
"core_sales_growth_excluding_respiratory_testing_pct": 5.5,
"total_sales_growth_pct": 8.5
},
"non_gaap_source_accession": "0000313616-26-000201"
},
{
"fiscal_year": 2025,
"fiscal_quarter": 3,
"label": "Q3 FY2025",
"period_start": "2025-06-28",
"period_end": "2025-09-26",
"period_type": "three months",
"source_accession": "0000313616-26-000199",
"income_statement": {
"revenue": 6053000000,
"cost_of_sales": 2530000000,
"gross_profit": 3523000000,
"selling_general_and_administrative_expenses": 1991000000,
"research_and_development_expenses": 378000000,
"operating_profit": 1154000000,
"other_income_expense_net": -14000000,
"interest_expense": 67000000,
"interest_income": 3000000,
"earnings_from_continuing_operations_before_income_taxes": 1076000000,
"income_tax_expense": 168000000,
"net_earnings_from_continuing_operations": 908000000,
"earnings_from_discontinued_operations_net_of_tax": 0,
"net_earnings": 908000000,
"basic_eps_continuing_operations": 1.28,
"diluted_eps_continuing_operations": 1.27,
"basic_eps_discontinued_operations": 0,
"diluted_eps_discontinued_operations": 0,
"basic_eps": 1.28,
"diluted_eps": 1.27,
"basic_shares": 710700000,
"diluted_shares": 713700000
},
"cash_flow": {
"operating_cash_flow": 1662000000,
"capital_expenditures": 292000000,
"proceeds_from_sales_of_property_plant_and_equipment": 0,
"net_cash_from_investing_activities_continuing_operations": -312000000,
"net_cash_from_financing_activities_continuing_operations": -2781000000,
"free_cash_flow": 1370000000
},
"cash_flow_source_accession": "0000313616-26-000201",
"shareholder_returns": {
"common_stock_dividends_declared": 227000000,
"repurchase_of_common_stock_including_excise_tax": 2030000000
},
"segments": {
"biotechnology": {
"sales": 1798000000,
"operating_profit": 352000000
},
"life_sciences": {
"sales": 1792000000,
"operating_profit": 222000000
},
"diagnostics": {
"sales": 2463000000,
"operating_profit": 665000000
},
"total_reportable_segments": {
"sales": 6053000000,
"operating_profit": 1239000000
},
"other_unallocated_corporate": {
"operating_profit": -85000000
}
},
"non_gaap": {
"adjusted_diluted_eps_continuing_operations": 1.89,
"free_cash_flow_company_definition": 1370000000
},
"non_gaap_source_accession": "0000313616-26-000201"
}
],
"year_to_date": {
"fiscal_year": 2026,
"label": "Nine months ended September 25, 2026",
"period_start": "2026-01-01",
"period_end": "2026-09-25",
"period_type": "nine months",
"source_accession": "0000313616-26-000199",
"income_statement": {
"revenue": 18770000000,
"cost_of_sales": 7731000000,
"gross_profit": 11039000000,
"selling_general_and_administrative_expenses": 6091000000,
"research_and_development_expenses": 1232000000,
"operating_profit": 3716000000,
"other_income_expense_net": -85000000,
"interest_expense": 305000000,
"interest_income": 119000000,
"earnings_from_continuing_operations_before_income_taxes": 3445000000,
"income_tax_expense": 339000000,
"net_earnings_from_continuing_operations": 3106000000,
"earnings_from_discontinued_operations_net_of_tax": 28000000,
"net_earnings": 3134000000,
"basic_eps_continuing_operations": 4.4,
"diluted_eps_continuing_operations": 4.38,
"basic_eps_discontinued_operations": 0.04,
"diluted_eps_discontinued_operations": 0.04,
"basic_eps": 4.44,
"diluted_eps": 4.42,
"basic_shares": 705700000,
"diluted_shares": 708500000
},
"cash_flow": {
"depreciation": 597000000,
"amortization_of_intangible_assets": 1410000000,
"stock_based_compensation": 266000000,
"impairment_charges": 52000000,
"operating_cash_flow": 4742000000,
"cash_paid_for_acquisitions": 9881000000,
"capital_expenditures": 761000000,
"proceeds_from_sales_of_property_plant_and_equipment": 1000000,
"net_cash_from_investing_activities_continuing_operations": -10696000000,
"dividends_paid": 790000000,
"net_proceeds_from_borrowings_maturities_of_90_days_or_less": 3666000000,
"borrowings_maturities_longer_than_90_days": 6555000000,
"repayments_of_borrowings_maturities_longer_than_90_days": 1434000000,
"payments_for_repurchase_of_common_stock": 894000000,
"net_cash_from_financing_activities_continuing_operations": 7057000000,
"free_cash_flow": 3981000000
},
"shareholder_returns": {
"common_stock_dividends_declared": 846000000,
"repurchase_of_common_stock_including_excise_tax": 903000000,
"dividends_paid": 790000000,
"payments_for_repurchase_of_common_stock": 894000000
},
"segments": {
"biotechnology": {
"sales": 5524000000,
"operating_profit": 1567000000
},
"life_sciences": {
"sales": 5481000000,
"operating_profit": 728000000
},
"diagnostics": {
"sales": 7765000000,
"operating_profit": 1704000000
},
"total_reportable_segments": {
"sales": 18770000000,
"operating_profit": 3999000000
},
"other_unallocated_corporate": {
"operating_profit": -283000000
}
},
"non_gaap": {
"adjusted_diluted_eps_continuing_operations": 6.11,
"free_cash_flow_company_definition": 3982000000,
"core_sales_growth_pct": 2.0,
"core_sales_growth_excluding_respiratory_testing_pct": 4.5,
"total_sales_growth_pct": 6.0
},
"non_gaap_source_accession": "0000313616-26-000201",
"prior_year_comparative": {
"fiscal_year": 2025,
"label": "Nine months ended September 26, 2025",
"period_start": "2025-01-01",
"period_end": "2025-09-26",
"period_type": "nine months",
"source_accession": "0000313616-26-000199",
"income_statement": {
"revenue": 17730000000,
"cost_of_sales": 7173000000,
"gross_profit": 10557000000,
"selling_general_and_administrative_expenses": 6209000000,
"research_and_development_expenses": 1160000000,
"operating_profit": 3188000000,
"other_income_expense_net": -135000000,
"interest_expense": 210000000,
"interest_income": 17000000,
"earnings_from_continuing_operations_before_income_taxes": 2860000000,
"income_tax_expense": 443000000,
"net_earnings_from_continuing_operations": 2417000000,
"earnings_from_discontinued_operations_net_of_tax": 0,
"net_earnings": 2417000000,
"basic_eps_continuing_operations": 3.38,
"diluted_eps_continuing_operations": 3.37,
"basic_eps_discontinued_operations": 0,
"diluted_eps_discontinued_operations": 0,
"basic_eps": 3.38,
"diluted_eps": 3.37,
"basic_shares": 714500000,
"diluted_shares": 717900000
},
"cash_flow": {
"depreciation": 555000000,
"amortization_of_intangible_assets": 1269000000,
"stock_based_compensation": 235000000,
"impairment_charges": 548000000,
"operating_cash_flow": 4299000000,
"cash_paid_for_acquisitions": 0,
"capital_expenditures": 785000000,
"proceeds_from_sales_of_property_plant_and_equipment": 10000000,
"net_cash_from_investing_activities_continuing_operations": -812000000,
"dividends_paid": 652000000,
"net_proceeds_from_borrowings_maturities_of_90_days_or_less": 22000000,
"borrowings_maturities_longer_than_90_days": 4000000,
"repayments_of_borrowings_maturities_longer_than_90_days": 500000000,
"payments_for_repurchase_of_common_stock": 3088000000,
"net_cash_from_financing_activities_continuing_operations": -4283000000,
"free_cash_flow": 3514000000
},
"shareholder_returns": {
"common_stock_dividends_declared": 685000000,
"repurchase_of_common_stock_including_excise_tax": 3112000000,
"dividends_paid": 652000000,
"payments_for_repurchase_of_common_stock": 3088000000
},
"segments": {
"biotechnology": {
"sales": 5260000000,
"operating_profit": 1324000000
},
"life_sciences": {
"sales": 5249000000,
"operating_profit": 184000000
},
"diagnostics": {
"sales": 7221000000,
"operating_profit": 1937000000
},
"total_reportable_segments": {
"sales": 17730000000,
"operating_profit": 3445000000
},
"other_unallocated_corporate": {
"operating_profit": -257000000
}
},
"non_gaap": {
"adjusted_diluted_eps_continuing_operations": 5.57,
"free_cash_flow_company_definition": 3524000000
},
"non_gaap_source_accession": "0000313616-26-000201"
}
},
"trailing_twelve_months": {
"label": "Twelve months ended September 25, 2026",
"period_start": "2025-09-27",
"period_end": "2026-09-25",
"period_type": "trailing twelve months",
"source_accession": "0000313616-26-000199",
"derived_from_accessions": [
"0000313616-26-000062",
"0000313616-26-000199"
],
"income_statement": {
"revenue": 25608000000,
"cost_of_sales": 10603000000,
"gross_profit": 15005000000,
"selling_general_and_administrative_expenses": 8117000000,
"research_and_development_expenses": 1670000000,
"operating_profit": 5218000000,
"other_income_expense_net": -172000000,
"interest_expense": 360000000,
"interest_income": 132000000,
"earnings_from_continuing_operations_before_income_taxes": 4818000000,
"income_tax_expense": 529000000,
"net_earnings_from_continuing_operations": 4289000000,
"earnings_from_discontinued_operations_net_of_tax": 42000000,
"net_earnings": 4331000000
},
"cash_flow": {
"operating_cash_flow": 6859000000,
"capital_expenditures": 1132000000,
"proceeds_from_sales_of_property_plant_and_equipment": 24000000,
"depreciation": 792000000,
"amortization_of_intangible_assets": 1838000000,
"cash_paid_for_acquisitions": 9881000000,
"dividends_paid": 1016000000,
"payments_for_repurchase_of_common_stock": 894000000,
"free_cash_flow": 5727000000
}
},
"notes": [
"Annual figures come from Danaher's FY2025 Form 10-K (accession 0000313616-26-000062): statements of earnings and cash flows for 2025, 2024 and 2023, and balance sheets as of December 31, 2025 and 2024. FY2023 therefore carries no balance sheet, because this 10-K does not print one for that date.",
"Quarterly, nine-month and balance-sheet figures for 2026 come from the Q3 2026 Form 10-Q (accession 0000313616-26-000199), which presents the three and nine months ended September 25, 2026 and September 26, 2025. Its December 31, 2025 balance-sheet column matches the 10-K line for line.",
"The 10-Q's cash flow statement covers only the nine-month periods. The three-month cash flow figures for Q3 FY2026 and Q3 FY2025 (operating, investing and financing cash flow, capital expenditures and disposal proceeds) therefore come from the Q3 2026 earnings release furnished as Exhibit 99.1 to the 8-K filed October 21, 2026 (accession 0000313616-26-000201). Each quarter records this as its cash_flow_source_accession. The release's nine-month operating cash flow and capital expenditures agree with the 10-Q.",
"Non-GAAP figures (adjusted diluted EPS from continuing operations, Danaher's own definition of free cash flow, and core sales growth) are as Danaher reports them in the same earnings release (accession 0000313616-26-000201). They are not GAAP measures.",
"Danaher's fiscal year ends December 31, and its interim quarters end on a Friday close to the calendar quarter-end. Q3 FY2026 runs from June 27 to September 25, 2026, and Q3 FY2025 from June 28 to September 26, 2025. The second quarters ended June 26, 2026 and June 27, 2025, according to the Q2 2026 earnings release (accession 0000313616-26-000163).",
"On June 10, 2026 Danaher acquired Masimo Corporation for a cash purchase price of approximately $9.8 billion, net of cash acquired, and reports it in the Diagnostics segment (10-Q Note 2). The acquisition accounts for most of the $9,881 million of cash paid for acquisitions in the nine months, and it drove the increase in goodwill and other intangible assets. It also drove higher borrowing: total debt rose to $26,482 million at September 25, 2026 from $18,418 million at December 31, 2025. According to the earnings release, acquisitions contributed 6.5 percentage points of the quarter's 8.5% total sales growth.",
"Q3 FY2026 income taxes were a net benefit of $75 million, against a $168 million expense a year earlier. The earnings release attributes this to net discrete tax benefits of $263 million in the quarter, related primarily to the release of reserves for uncertain tax positions following audit settlements. Separately, the quarter's $28 million of earnings from discontinued operations is an income tax benefit from releasing reserves on tax returns that were filed jointly with Veralto Corporation and Fortive Corporation entities before those businesses separated (10-Q Note 3).",
"FY2023 includes Veralto Corporation, which was separated in 2023, as a discontinued operation: $543 million of earnings from discontinued operations, $674 million of operating cash flow from discontinued operations, and $21 million of mandatory convertible preferred stock dividends deducted to reach earnings attributable to common stockholders. FY2023 diluted EPS of $6.38 is struck on that $4,743 million.",
"Operating cash flow throughout this record is cash from continuing operations, the basis the 10-Q and the earnings release use. For the annual periods, operating_cash_flow_including_discontinued_operations also gives the 10-K's total (FY2023: $7,164 million against $6,490 million from continuing operations).",
"Free cash flow here is operating cash flow from continuing operations less capital expenditures. Danaher's own non-GAAP free cash flow also adds back proceeds from sales of property, plant and equipment, so it can differ slightly: Q3 FY2026 is $1,632 million as Danaher reports it and $1,631 million here. Danaher's figure appears under non_gaap.free_cash_flow_company_definition.",
"Segment operating profit is as reported in the segment note of each filing. other_unallocated_corporate is unallocated corporate costs and other costs not considered part of segment performance; together with the three segments, it sums to consolidated operating profit in every period.",
"The trailing twelve months to September 25, 2026 is derived as FY2025 plus the nine months of 2026, minus the nine months of 2025. It carries no per-share figures, because EPS does not sum across periods.",
"Common stock dividends declared and repurchases including excise tax come from the statements of stockholders' equity. Dividends paid and payments for repurchases come from the cash flow statements, and the two can differ in timing.",
"As the 10-Q's own footnote states, nine-month EPS amounts do not equal the sum of the three-month amounts because of rounding.",
"After the quarter closed, on September 28, 2026, Danaher acquired StatLab Medical Products for approximately $1.4 billion, including assumed indebtedness and net of acquired cash (10-Q Note 2, subsequent event). It is not reflected in any figure here."
],
"uncertainties": [
"The three-month cash flow figures for Q3 FY2026 and Q3 FY2025 come from the earnings release. No filed financial statement prints them, because the 10-Q's cash flow statement is nine-month only, so they cannot be confirmed against a statement. The release's nine-month figures do agree with the 10-Q.",
"The Q3 FY2025 quarter carries no balance sheet, because the Q3 2026 10-Q compares the September 25, 2026 balance sheet with December 31, 2025, not with September 26, 2025."
],
"headline": {
"period": "Q3 FY2026",
"period_end_words": "September 25, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 6554000000,
"text": "$6.55 billion",
"exact": "$6,554,000,000",
"compact": "$6.55B",
"abs": "$6.55 billion",
"prior_value": 6053000000,
"prior": "$6.05 billion",
"priorabs": "$6.05 billion",
"yoy": "up 8.3%",
"source": {
"array": "quarterly",
"field": "income_statement.revenue",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
},
{
"label": "Net earnings",
"format": "usd",
"value": 1235000000,
"text": "$1.24 billion",
"exact": "$1,235,000,000",
"compact": "$1.24B",
"abs": "$1.24 billion",
"prior_value": 908000000,
"prior": "$908 million",
"priorabs": "$908 million",
"yoy": "up 36.0%",
"source": {
"array": "quarterly",
"field": "income_statement.net_earnings",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 1.75,
"text": "$1.75",
"exact": "$1.75",
"compact": "$1.75",
"abs": "$1.75",
"prior_value": 1.27,
"prior": "$1.27",
"priorabs": "$1.27",
"yoy": "up 37.8%",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
},
{
"label": "Operating profit",
"format": "usd",
"value": 1245000000,
"text": "$1.25 billion",
"exact": "$1,245,000,000",
"compact": "$1.25B",
"abs": "$1.25 billion",
"prior_value": 1154000000,
"prior": "$1.15 billion",
"priorabs": "$1.15 billion",
"yoy": "up 7.9%",
"source": {
"array": "quarterly",
"field": "income_statement.operating_profit",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
},
{
"label": "Diagnostics sales",
"format": "usd",
"value": 2882000000,
"text": "$2.88 billion",
"exact": "$2,882,000,000",
"compact": "$2.88B",
"abs": "$2.88 billion",
"prior_value": 2463000000,
"prior": "$2.46 billion",
"priorabs": "$2.46 billion",
"yoy": "up 17.0%",
"source": {
"array": "quarterly",
"field": "segments.diagnostics.sales",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
},
{
"label": "Diagnostics operating profit",
"format": "usd",
"value": 614000000,
"text": "$614 million",
"exact": "$614,000,000",
"compact": "$614.00M",
"abs": "$614 million",
"prior_value": 665000000,
"prior": "$665 million",
"priorabs": "$665 million",
"yoy": "down 7.7%",
"source": {
"array": "quarterly",
"field": "segments.diagnostics.operating_profit",
"index": 0,
"period_label": "Q3 FY2026",
"period_end": "2026-09-25",
"period_start": "2026-06-27",
"span_days": 90,
"source_accession": "0000313616-26-000199",
"prior_index": 1,
"prior_period_label": "Q3 FY2025",
"prior_period_end": "2025-09-26",
"prior_period_start": "2025-06-28",
"prior_span_days": 90,
"prior_source_accession": "0000313616-26-000199",
"gap_days": 364
}
}
],
"summary": "Danaher reported $6.55 billion in revenue for Q3 FY2026, the quarter ended September 25, 2026, up 8.3% from a year earlier, with acquisitions, chiefly Masimo, accounting for most of the growth. Net earnings were $1.24 billion, or $1.75 per diluted share, up 36.0% from $908 million, but most of that gain came from a one-time tax benefit from releasing reserves for uncertain tax positions after audit settlements. Operating profit was $1.25 billion, up 7.9%, a much smaller gain that came from Biotechnology and Life Sciences; Masimo lifted Diagnostics sales to $2.88 billion, but lower-margin acquired businesses and the Masimo inventory step-up cut Diagnostics operating profit to $614 million, down 7.7%.",
"qa": [
{
"q": "How much revenue did Danaher report in Q3 FY2026?",
"a": "Danaher reported $6.55 billion in revenue for Q3 FY2026, the quarter ended September 25, 2026, up 8.3% from $6.05 billion a year earlier. Acquisitions, chiefly Masimo, accounted for most of that growth."
},
{
"q": "What was Danaher's net income in Q3 FY2026?",
"a": "Danaher's net earnings were $1.24 billion in Q3 FY2026, up 36.0% from $908 million a year earlier. Most of the increase came from a one-time tax benefit from releasing reserves for uncertain tax positions, while Danaher's operating profit was $1.25 billion, up 7.9%."
},
{
"q": "What was Danaher's diluted EPS in Q3 FY2026?",
"a": "Danaher earned $1.75 per diluted share in Q3 FY2026, including discontinued operations, up 37.8% from $1.27 a year earlier. The figure includes a one-time tax benefit from released reserves for uncertain tax positions."
},
{
"q": "How did the Masimo acquisition affect Danaher's results in Q3 FY2026?",
"a": "Danaher completed its purchase of Masimo in June and reports it in its Diagnostics segment, whose sales were $2.88 billion in Q3 FY2026, up 17.0% from $2.46 billion a year earlier, with acquisitions accounting for nearly all of that growth. Diagnostics operating profit fell to $614 million from $665 million, and the segment's operating margin narrowed, as lower-margin acquired businesses and the Masimo inventory step-up weighed on it."
}
]
},
"company_details": {
"Name": "Danaher Corp /De/",
"Ticker": "DHR",
"CIK": "0000313616",
"Exchange": "NYSE",
"State": "District of Columbia",
"Incorporation": "Delaware",
"SIC": "3823",
"Office": "Industrial Applications and Services",
"Industry": "Industrial Instruments For Measurement, Display, and Control"
},
"next_filing": {
"predicted_date": "2027-02-23",
"predicted_type": "10-K"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-09-25",
"form": "10-Q",
"accession": "0000313616-26-000199",
"fiscal_year_end": "1231",
"source": "facts"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "10-K",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-12-31",
"filed": "2026-02-24",
"accession": "0000313616-26-000062",
"url": "https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "10-Q",
"fiscal_year": 2026,
"fiscal_period": "Q3",
"tag": "FY26Q3",
"period_end": "2026-09-25",
"filed": "2026-10-21",
"accession": "0000313616-26-000199",
"url": "https://www.sec.gov/Archives/edgar/data/313616/000031361626000199/dhr-20260925.htm",
"source": "facts"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm",
"d2": "https://www.sec.gov/Archives/edgar/data/313616/000031361626000199/dhr-20260925.htm"
},
"annual": [
{
"period_end": "2025-12-31",
"income_statement": {
"revenue": "d1#f-141",
"cost_of_sales": "d1#f-144",
"gross_profit": "d1#f-147",
"selling_general_and_administrative_expenses": "d1#f-150",
"research_and_development_expenses": "d1#f-153",
"operating_profit": "d1#f-156",
"other_income_expense_net": "d1#f-159",
"interest_expense": "d1#f-162",
"interest_income": "d1#f-165",
"earnings_from_continuing_operations_before_income_taxes": "d1#f-168",
"income_tax_expense": "d1#f-171",
"net_earnings_from_continuing_operations": "d1#f-174",
"earnings_from_discontinued_operations_net_of_tax": "d1#f-177",
"net_earnings": "d1#f-180",
"basic_eps_continuing_operations": "d1#f-189",
"diluted_eps_continuing_operations": "d1#f-192",
"basic_eps_discontinued_operations": "d1#f-195",
"diluted_eps_discontinued_operations": "d1#f-198",
"basic_eps": "d1#f-201",
"diluted_eps": "d1#f-204",
"basic_shares": "d1#f-207",
"diluted_shares": "d1#f-210",
"net_earnings_attributable_to_common_stockholders": "d1#f-186"
},
"balance_sheet": {
"cash_and_equivalents": "d1#f-81",
"trade_accounts_receivable_net": "d1#f-85",
"inventories": "d1#f-87",
"prepaid_expenses_and_other_current_assets": "d1#f-89",
"total_current_assets": "d1#f-91",
"property_plant_and_equipment_net": "d1#f-93",
"other_long_term_assets": "d1#f-95",
"goodwill": "d1#f-97",
"other_intangible_assets_net": "d1#f-99",
"total_assets": "d1#f-101",
"notes_payable_and_current_portion_of_long_term_debt": "d1#f-103",
"trade_accounts_payable": "d1#f-105",
"accrued_expenses_and_other_liabilities": "d1#f-107",
"total_current_liabilities": "d1#f-109",
"other_long_term_liabilities": "d1#f-111",
"long_term_debt": "d1#f-113",
"common_stock": "d1#f-123",
"additional_paid_in_capital": "d1#f-125",
"treasury_stock": "d1#f-127",
"retained_earnings": "d1#f-129",
"accumulated_other_comprehensive_income_loss": "d1#f-131",
"total_danaher_stockholders_equity": "d1#f-133",
"noncontrolling_interests": "d1#f-135",
"total_equity": "d1#f-137",
"total_debt": "d1#f-1504",
"shares_outstanding": "d1#f-120"
},
"cash_flow": {
"depreciation": "d1#f-330",
"amortization_of_intangible_assets": "d1#f-333",
"stock_based_compensation": "d1#f-339",
"impairment_charges": "d1#f-345",
"operating_cash_flow": "d1#f-372",
"operating_cash_flow_including_discontinued_operations": "d1#f-366",
"capital_expenditures": "d1#f-877",
"proceeds_from_sales_of_property_plant_and_equipment": "d1#f-381",
"net_cash_from_investing_activities_continuing_operations": "d1#f-396",
"dividends_paid": "d1#f-408",
"borrowings_maturities_longer_than_90_days": "d1#f-414",
"repayments_of_borrowings_maturities_longer_than_90_days": "d1#f-417",
"payments_for_repurchase_of_common_stock": "d1#f-423",
"net_cash_from_financing_activities_continuing_operations": "d1#f-429"
},
"shareholder_returns": {
"common_stock_dividends_declared": "d1#f-282",
"repurchase_of_common_stock_including_excise_tax": "d1#f-267",
"dividends_paid": "d1#f-408",
"payments_for_repurchase_of_common_stock": "d1#f-423"
},
"segments": {
"biotechnology": {
"sales": "d1#f-742",
"operating_profit": "d1#f-772"
},
"life_sciences": {
"sales": "d1#f-743",
"operating_profit": "d1#f-773"
},
"diagnostics": {
"sales": "d1#f-744",
"operating_profit": "d1#f-774"
},
"total_reportable_segments": {
"sales": "d1#f-747",
"operating_profit": "d1#f-775"
},
"other_unallocated_corporate": {
"operating_profit": "d1#f-776"
}
}
},
{
"period_end": "2024-12-31",
"income_statement": {
"revenue": "d1#f-142",
"cost_of_sales": "d1#f-145",
"gross_profit": "d1#f-148",
"selling_general_and_administrative_expenses": "d1#f-151",
"research_and_development_expenses": "d1#f-154",
"operating_profit": "d1#f-157",
"other_income_expense_net": "d1#f-160",
"interest_expense": "d1#f-163",
"interest_income": "d1#f-166",
"earnings_from_continuing_operations_before_income_taxes": "d1#f-169",
"income_tax_expense": "d1#f-172",
"net_earnings_from_continuing_operations": "d1#f-175",
"net_earnings": "d1#f-181",
"basic_eps_continuing_operations": "d1#f-190",
"diluted_eps_continuing_operations": "d1#f-193",
"basic_eps": "d1#f-202",
"diluted_eps": "d1#f-205",
"basic_shares": "d1#f-208",
"diluted_shares": "d1#f-211",
"net_earnings_attributable_to_common_stockholders": "d1#f-187"
},
"balance_sheet": {
"cash_and_equivalents": "d1#f-82",
"trade_accounts_receivable_net": "d1#f-86",
"inventories": "d1#f-88",
"prepaid_expenses_and_other_current_assets": "d1#f-90",
"total_current_assets": "d1#f-92",
"property_plant_and_equipment_net": "d1#f-94",
"other_long_term_assets": "d1#f-96",
"goodwill": "d1#f-98",
"other_intangible_assets_net": "d1#f-100",
"total_assets": "d1#f-102",
"notes_payable_and_current_portion_of_long_term_debt": "d1#f-104",
"trade_accounts_payable": "d1#f-106",
"accrued_expenses_and_other_liabilities": "d1#f-108",
"total_current_liabilities": "d1#f-110",
"other_long_term_liabilities": "d1#f-112",
"long_term_debt": "d1#f-114",
"common_stock": "d1#f-124",
"additional_paid_in_capital": "d1#f-126",
"treasury_stock": "d1#f-128",
"retained_earnings": "d1#f-130",
"accumulated_other_comprehensive_income_loss": "d1#f-132",
"total_danaher_stockholders_equity": "d1#f-134",
"noncontrolling_interests": "d1#f-136",
"total_equity": "d1#f-138",
"total_debt": "d1#f-1505",
"shares_outstanding": "d1#f-122"
},
"cash_flow": {
"depreciation": "d1#f-331",
"amortization_of_intangible_assets": "d1#f-334",
"stock_based_compensation": "d1#f-340",
"impairment_charges": "d1#f-346",
"operating_cash_flow": "d1#f-373",
"operating_cash_flow_including_discontinued_operations": "d1#f-367",
"cash_paid_for_acquisitions": "d1#f-376",
"capital_expenditures": "d1#f-878",
"proceeds_from_sales_of_property_plant_and_equipment": "d1#f-382",
"net_cash_from_investing_activities_continuing_operations": "d1#f-397",
"dividends_paid": "d1#f-409",
"repayments_of_borrowings_maturities_longer_than_90_days": "d1#f-418",
"payments_for_repurchase_of_common_stock": "d1#f-424",
"net_cash_from_financing_activities_continuing_operations": "d1#f-430"
},
"shareholder_returns": {
"common_stock_dividends_declared": "d1#f-283",
"repurchase_of_common_stock_including_excise_tax": "d1#f-268",
"dividends_paid": "d1#f-409",
"payments_for_repurchase_of_common_stock": "d1#f-424"
},
"segments": {
"biotechnology": {
"sales": "d1#f-778",
"operating_profit": "d1#f-808"
},
"life_sciences": {
"sales": "d1#f-779",
"operating_profit": "d1#f-809"
},
"diagnostics": {
"sales": "d1#f-780",
"operating_profit": "d1#f-810"
},
"total_reportable_segments": {
"sales": "d1#f-783",
"operating_profit": "d1#f-811"
},
"other_unallocated_corporate": {
"operating_profit": "d1#f-812"
}
}
},
{
"period_end": "2023-12-31",
"income_statement": {
"revenue": "d1#f-143",
"cost_of_sales": "d1#f-146",
"gross_profit": "d1#f-149",
"selling_general_and_administrative_expenses": "d1#f-152",
"research_and_development_expenses": "d1#f-155",
"operating_profit": "d1#f-158",
"other_income_expense_net": "d1#f-161",
"interest_expense": "d1#f-164",
"interest_income": "d1#f-167",
"earnings_from_continuing_operations_before_income_taxes": "d1#f-170",
"income_tax_expense": "d1#f-173",
"net_earnings_from_continuing_operations": "d1#f-176",
"earnings_from_discontinued_operations_net_of_tax": "d1#f-179",
"net_earnings": "d1#f-182",
"basic_eps_continuing_operations": "d1#f-191",
"diluted_eps_continuing_operations": "d1#f-194",
"basic_eps_discontinued_operations": "d1#f-197",
"diluted_eps_discontinued_operations": "d1#f-200",
"basic_eps": "d1#f-203",
"diluted_eps": "d1#f-206",
"basic_shares": "d1#f-209",
"diluted_shares": "d1#f-212",
"preferred_stock_dividends": "d1#f-185",
"net_earnings_attributable_to_common_stockholders": "d1#f-188"
},
"cash_flow": {
"depreciation": "d1#f-332",
"amortization_of_intangible_assets": "d1#f-335",
"stock_based_compensation": "d1#f-341",
"impairment_charges": "d1#f-347",
"operating_cash_flow": "d1#f-368",
"operating_cash_flow_including_discontinued_operations": "d1#f-374",
"cash_paid_for_acquisitions": "d1#f-377",
"capital_expenditures": "d1#f-879",
"proceeds_from_sales_of_property_plant_and_equipment": "d1#f-383",
"net_cash_from_investing_activities_continuing_operations": "d1#f-398",
"dividends_paid": "d1#f-410",
"repayments_of_borrowings_maturities_longer_than_90_days": "d1#f-419",
"net_cash_from_financing_activities_continuing_operations": "d1#f-431"
},
"shareholder_returns": {
"common_stock_dividends_declared": "d1#f-284",
"dividends_paid": "d1#f-410"
},
"segments": {
"biotechnology": {
"sales": "d1#f-814",
"operating_profit": "d1#f-844"
},
"life_sciences": {
"sales": "d1#f-815",
"operating_profit": "d1#f-845"
},
"diagnostics": {
"sales": "d1#f-816",
"operating_profit": "d1#f-846"
},
"total_reportable_segments": {
"sales": "d1#f-819",
"operating_profit": "d1#f-847"
},
"other_unallocated_corporate": {
"operating_profit": "d1#f-353"
}
}
}
],
"quarterly": [
{
"period_end": "2026-09-25",
"income_statement": {
"revenue": "d2#f-131",
"cost_of_sales": "d2#f-135",
"gross_profit": "d2#f-139",
"selling_general_and_administrative_expenses": "d2#f-143",
"research_and_development_expenses": "d2#f-147",
"operating_profit": "d2#f-151",
"other_income_expense_net": "d2#f-155",
"interest_expense": "d2#f-159",
"interest_income": "d2#f-163",
"earnings_from_continuing_operations_before_income_taxes": "d2#f-167",
"income_tax_expense": "d2#f-171",
"net_earnings_from_continuing_operations": "d2#f-175",
"earnings_from_discontinued_operations_net_of_tax": "d2#f-179",
"net_earnings": "d2#f-183",
"basic_eps_continuing_operations": "d2#f-187",
"diluted_eps_continuing_operations": "d2#f-191",
"basic_eps_discontinued_operations": "d2#f-195",
"diluted_eps_discontinued_operations": "d2#f-199",
"basic_eps": "d2#f-203",
"diluted_eps": "d2#f-207",
"basic_shares": "d2#f-211",
"diluted_shares": "d2#f-215"
},
"balance_sheet": {
"cash_and_equivalents": "d2#f-63",
"trade_accounts_receivable_net": "d2#f-67",
"inventories": "d2#f-75",
"prepaid_expenses_and_other_current_assets": "d2#f-77",
"total_current_assets": "d2#f-79",
"property_plant_and_equipment_net": "d2#f-83",
"other_long_term_assets": "d2#f-85",
"goodwill": "d2#f-87",
"other_intangible_assets_net": "d2#f-89",
"total_assets": "d2#f-91",
"notes_payable_and_current_portion_of_long_term_debt": "d2#f-93",
"trade_accounts_payable": "d2#f-95",
"accrued_expenses_and_other_liabilities": "d2#f-97",
"total_current_liabilities": "d2#f-99",
"other_long_term_liabilities": "d2#f-101",
"long_term_debt": "d2#f-103",
"common_stock": "d2#f-113",
"additional_paid_in_capital": "d2#f-115",
"treasury_stock": "d2#f-117",
"retained_earnings": "d2#f-119",
"accumulated_other_comprehensive_income_loss": "d2#f-121",
"total_danaher_stockholders_equity": "d2#f-123",
"noncontrolling_interests": "d2#f-125",
"total_equity": "d2#f-127",
"total_debt": "d2#f-1169",
"shares_outstanding": "d2#f-110"
},
"cash_flow": {
"capital_expenditures": "d2#f-848",
"proceeds_from_sales_of_property_plant_and_equipment": "d2#f-1445"
},
"shareholder_returns": {
"common_stock_dividends_declared": "d2#f-291"
},
"segments": {
"biotechnology": {
"sales": "d2#f-666",
"operating_profit": "d2#f-702"
},
"life_sciences": {
"sales": "d2#f-667",
"operating_profit": "d2#f-703"
},
"diagnostics": {
"sales": "d2#f-668",
"operating_profit": "d2#f-704"
},
"total_reportable_segments": {
"sales": "d2#f-671",
"operating_profit": "d2#f-705"
},
"other_unallocated_corporate": {
"operating_profit": "d2#f-706"
}
}
},
{
"period_end": "2025-09-26",
"income_statement": {
"revenue": "d2#f-132",
"cost_of_sales": "d2#f-136",
"gross_profit": "d2#f-140",
"selling_general_and_administrative_expenses": "d2#f-144",
"research_and_development_expenses": "d2#f-148",
"operating_profit": "d2#f-152",
"other_income_expense_net": "d2#f-156",
"interest_expense": "d2#f-160",
"interest_income": "d2#f-164",
"earnings_from_continuing_operations_before_income_taxes": "d2#f-168",
"income_tax_expense": "d2#f-172",
"net_earnings_from_continuing_operations": "d2#f-176",
"net_earnings": "d2#f-184",
"basic_eps_continuing_operations": "d2#f-188",
"diluted_eps_continuing_operations": "d2#f-192",
"basic_eps": "d2#f-204",
"diluted_eps": "d2#f-208",
"basic_shares": "d2#f-212",
"diluted_shares": "d2#f-216"
},
"cash_flow": {
"capital_expenditures": "d2#f-849"
},
"shareholder_returns": {
"common_stock_dividends_declared": "d2#f-292",
"repurchase_of_common_stock_including_excise_tax": "d2#f-272"
},
"segments": {
"biotechnology": {
"sales": "d2#f-708",
"operating_profit": "d2#f-738"
},
"life_sciences": {
"sales": "d2#f-709",
"operating_profit": "d2#f-739"
},
"diagnostics": {
"sales": "d2#f-710",
"operating_profit": "d2#f-740"
},
"total_reportable_segments": {
"sales": "d2#f-713",
"operating_profit": "d2#f-741"
},
"other_unallocated_corporate": {
"operating_profit": "d2#f-742"
}
}
}
]
}
}